TSWIFT, a novel method for iterative staining of embedded and mounted human brain sections.

Sci Rep

Department of Molecular and Integrative Physiology, University of Michigan, BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109, USA.

Published: June 2024

Comprehensive characterization of protein networks in mounted brain tissue represents a major challenge in brain and neurodegenerative disease research. In this study, we develop a simple staining method, called TSWIFT, to iteratively stain pre-mounted formalin fixed, paraffin embedded (FFPE) brain sections, thus enabling high-dimensional sample phenotyping. We show that TSWIFT conserves tissue architecture and allows for relabeling a single mounted FFPE sample more than 10 times, even after prolonged storage at 4 °C. Our results establish TSWIFT as an efficient method to obtain integrated high-dimensional knowledge of cellular proteomes by analyzing mounted FFPE human brain tissue.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11148033PMC
http://dx.doi.org/10.1038/s41598-024-63152-2DOI Listing

Publication Analysis

Top Keywords

human brain
8
brain sections
8
brain tissue
8
mounted ffpe
8
brain
5
tswift
4
tswift novel
4
novel method
4
method iterative
4
iterative staining
4

Similar Publications

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder affecting multiple organ systems, with a prevalence of 1:6,760-1:13,520 live births in Germany. On the molecular level, TSC is caused by heterozygous loss-of-function variants in either of the genes TSC1 or TSC2, encoding the Tuberin-Hamartin complex, which acts as a critical upstream suppressor of the mammalian target of rapamycin (mTOR), a key signaling pathway controlling cellular growth and metabolism. Despite the therapeutic success of mTOR inhibition in treating TSC-associated manifestations, studies with mTOR inhibitors in children with TSC above two years of age have failed to demonstrate beneficial effects on disease-related neuropsychological deficits.

View Article and Find Full Text PDF

Background: Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life effectiveness and tolerability. GAINER, a prospective, multicentric study, aimed to evaluate rimegepant effectiveness and tolerability in the real-world setting.

View Article and Find Full Text PDF

Huntington's disease (HD) is caused by a CAG repeat expansion in the HTT gene, leading to altered gene expression. However, the mechanisms leading to disrupted RNA processing in HD remain unclear. Here we identify TDP-43 and the N6-methyladenosine (m6A) writer protein METTL3 to be upstream regulators of exon skipping in multiple HD systems.

View Article and Find Full Text PDF

Deep brain stimulation (DBS) effectively treats Parkinson's disease (PD) motor symptoms, highlighting a gap in understanding current research trends and future directions. This study aims to analyze DBS literature systematically using bibliometric methods to map trends and identify opportunities. A total of 6,041 publications on DBS for PD from 1993 to 2023 were retrieved from the Web of Science Core Collection (WoSCC) on July 24, 2023.

View Article and Find Full Text PDF

Cerebral hydatid disease, caused by Echinococcus granulosus, is uncommon in children but presents significant diagnostic challenges due to its potential to mimic malignancy. Only a handful of cases with such a dilemma have been reported yet in the literature. We report a case of a 12-year-old female presenting with progressive headache and seizures, initially suspected to be a pilocytic astrocytoma.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!